IBDEI2ZT ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,50172,2)
 ;;=^5015591
 ;;^UTILITY(U,$J,358.3,50173,0)
 ;;=N29.^^219^2443^16
 ;;^UTILITY(U,$J,358.3,50173,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50173,1,3,0)
 ;;=3^Kidney and Ureter Disorders in Diseases Classd Elsewhr
 ;;^UTILITY(U,$J,358.3,50173,1,4,0)
 ;;=4^N29.
 ;;^UTILITY(U,$J,358.3,50173,2)
 ;;=^5015631
 ;;^UTILITY(U,$J,358.3,50174,0)
 ;;=N15.8^^219^2443^25
 ;;^UTILITY(U,$J,358.3,50174,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50174,1,3,0)
 ;;=3^Renal Tubulo-Interstitial Diseases
 ;;^UTILITY(U,$J,358.3,50174,1,4,0)
 ;;=4^N15.8
 ;;^UTILITY(U,$J,358.3,50174,2)
 ;;=^5015595
 ;;^UTILITY(U,$J,358.3,50175,0)
 ;;=N14.4^^219^2443^26
 ;;^UTILITY(U,$J,358.3,50175,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50175,1,3,0)
 ;;=3^Toxic Nephropathy NEC
 ;;^UTILITY(U,$J,358.3,50175,1,4,0)
 ;;=4^N14.4
 ;;^UTILITY(U,$J,358.3,50175,2)
 ;;=^5015594
 ;;^UTILITY(U,$J,358.3,50176,0)
 ;;=N05.6^^219^2443^18
 ;;^UTILITY(U,$J,358.3,50176,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50176,1,3,0)
 ;;=3^Nephritic Syndrome w/ Dense Deposit Disease,Unspec
 ;;^UTILITY(U,$J,358.3,50176,1,4,0)
 ;;=4^N05.6
 ;;^UTILITY(U,$J,358.3,50176,2)
 ;;=^5015547
 ;;^UTILITY(U,$J,358.3,50177,0)
 ;;=N05.7^^219^2443^19
 ;;^UTILITY(U,$J,358.3,50177,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50177,1,3,0)
 ;;=3^Nephritic Syndrome w/ Diffuse Crescentic Glomerulonephritis,Unspec
 ;;^UTILITY(U,$J,358.3,50177,1,4,0)
 ;;=4^N05.7
 ;;^UTILITY(U,$J,358.3,50177,2)
 ;;=^5015548
 ;;^UTILITY(U,$J,358.3,50178,0)
 ;;=N05.1^^219^2443^20
 ;;^UTILITY(U,$J,358.3,50178,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50178,1,3,0)
 ;;=3^Nephritic Syndrome w/ Focal/Segmental Glomerular Lesions,Unspec
 ;;^UTILITY(U,$J,358.3,50178,1,4,0)
 ;;=4^N05.1
 ;;^UTILITY(U,$J,358.3,50178,2)
 ;;=^5015542
 ;;^UTILITY(U,$J,358.3,50179,0)
 ;;=N05.0^^219^2443^21
 ;;^UTILITY(U,$J,358.3,50179,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50179,1,3,0)
 ;;=3^Nephritic Syndrome w/ Minor Glomerular Abnormality,Unspec
 ;;^UTILITY(U,$J,358.3,50179,1,4,0)
 ;;=4^N05.0
 ;;^UTILITY(U,$J,358.3,50179,2)
 ;;=^5015541
 ;;^UTILITY(U,$J,358.3,50180,0)
 ;;=N05.8^^219^2443^22
 ;;^UTILITY(U,$J,358.3,50180,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50180,1,3,0)
 ;;=3^Nephritic Syndrome w/ Morphologic Changes,Unspec
 ;;^UTILITY(U,$J,358.3,50180,1,4,0)
 ;;=4^N05.8
 ;;^UTILITY(U,$J,358.3,50180,2)
 ;;=^5134085
 ;;^UTILITY(U,$J,358.3,50181,0)
 ;;=R59.9^^219^2444^4
 ;;^UTILITY(U,$J,358.3,50181,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50181,1,3,0)
 ;;=3^Enlarged Lymph Nodes,Unspec
 ;;^UTILITY(U,$J,358.3,50181,1,4,0)
 ;;=4^R59.9
 ;;^UTILITY(U,$J,358.3,50181,2)
 ;;=^5019531
 ;;^UTILITY(U,$J,358.3,50182,0)
 ;;=R59.1^^219^2444^2
 ;;^UTILITY(U,$J,358.3,50182,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50182,1,3,0)
 ;;=3^Enlarged Lymph Nodes,Generalized
 ;;^UTILITY(U,$J,358.3,50182,1,4,0)
 ;;=4^R59.1
 ;;^UTILITY(U,$J,358.3,50182,2)
 ;;=^5019530
 ;;^UTILITY(U,$J,358.3,50183,0)
 ;;=R59.0^^219^2444^3
 ;;^UTILITY(U,$J,358.3,50183,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50183,1,3,0)
 ;;=3^Enlarged Lymph Nodes,Localized
 ;;^UTILITY(U,$J,358.3,50183,1,4,0)
 ;;=4^R59.0
 ;;^UTILITY(U,$J,358.3,50183,2)
 ;;=^5019529
 ;;^UTILITY(U,$J,358.3,50184,0)
 ;;=Z79.01^^219^2444^5
 ;;^UTILITY(U,$J,358.3,50184,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50184,1,3,0)
 ;;=3^Long Term Use of Anticoagulants
 ;;^UTILITY(U,$J,358.3,50184,1,4,0)
 ;;=4^Z79.01
 ;;^UTILITY(U,$J,358.3,50184,2)
 ;;=^5063330
 ;;^UTILITY(U,$J,358.3,50185,0)
 ;;=D64.9^^219^2444^1
 ;;^UTILITY(U,$J,358.3,50185,1,0)
 ;;=^358.31IA^4^2
